Relative bioavailability of omeprazole capsules after oral dosing

Daru

Volumn 12, Issue 4, 2004, Pages 146-150

  Mostafavi, Sayed Abolfazl ^a   Tavakoli, Naser ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bioequivalence; Ethnic Disposition; Omeprazole; Pharmacokinetics

Indexed keywords

GENERIC DRUG; LORSEC; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; ENTERIC COATED TABLET; ETHNIC DIFFERENCE; HISPANIC; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARAMETER; RANDOMIZED CONTROLLED TRIAL;

EID: 13644255985     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Colin WH. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49.
2. Mctavish D, Buckley MMT, Heel RC. Omeprazole. Drugs 1991; 42: 138-170.
3. Watanabe K, Furuno K, Eto K, Oishi R, Gomit Y. First-Pass metabolism of omeprazole in rats. J Pharm Sci 1994; 83: 1131-1134.
4. Clissold SP, Campoli-Richards DM. Omeprazole: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peptic ulcer disease and Zollinger-Ellioson syndrome. Drugs 1986; 32: 15-47.
5. Regardh CG, Gabrielsson M, Hoffma KJ, Lofberg I, Skanberg I. Pharmacokinetics and metabolism of omeprazole in animals and man, an overview. Scand. J Gastroenterol suppl 1985; 108: 79-94.
6. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole- a gastric proton pump inhibitor- On pentagastrin-stimulated acid secretion in man. Gut 1983; 24: 270-276.
7. Londong W, Londong V, Cederberg C, Steffen H. Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterol 1983; 85: 1373-1378.
8. Prichard PJ, Yeomans ND, Mihaly GW, Jones DB, Buckle PJ. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterol 1985; 88: 64-49.
9. Lagerstrom PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984; 309: 347-56.
10. Mihaly GW, Prichard PJ, Smallwood RA, Yeomans ND, Louis WJ. Simultaneous high performance liquid chromatographic analysis of omeprazole and its sulphone and sulphide metabolites in human plasma and urine. J Chromatogr 1983; 278: 311-319.
11. Sohn DR, Kbayashi K, Chiba K, Lee K, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4 hydroxylation recruited from and oriental population. J Pharmacol Exp Ther 1992; 262: 1195-202.
12. Katashima M, Yamamoto K, Sugiura M, Sawada Y, IgA T. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Drug Metab Dispos 1995; 23 (7): 718-723
13. Savarino V, Mela GS, Zentilin P, Cutela P, Mele MR, Vigneri S, Celle G. Variability in individual response to various doses of omeprazole; implications for antiulcer therapy. Dig Dis Sci 1994; 39: 161-8.
14. Bioequivalence Food and Drug Administration. FDA guidelines. Bioequivalence Food and Drug Administration, Division of Bioequivalence Office of Generic Drugs: Rockville, MD, 1992 Guidelines.
15. Westlake WF. Use of confidence interval in analysis of comparative bioavailability trials. J Pharm Sci 1972; 61: 1340-1341.
16. Mandallaz D, Mau J. Comparison of different methods of decision making in bioequivalence assessments. Biometrics 1981; 37: 213-222.
17. Pillai GK, Sheikh SM, Najib NM, Jilani J. Bioequivalence study of two capsule formulation of omeprazole. Act Pharm Hung 1996; 66: 231-235.
18. Horai Y, Nakano m, Ishizaki T, Zhou HH, Zhou BJ, Liao CL, Zhang LM. Metoprolol and mephenytoin polymorphism in far eastern oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
19. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin P4 hydroxylation: Differences between Orientals and Caucasians. Br. J Clin Pharmacol 1985; 19: 483-487.
20. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
21. Alavan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphism of debrisoquin and mephenytoin in European populations. Eur. J Clin Pharmacol 1990; 39: 533-537.
22. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur. J Clin Pharmacol 1988; 35: 167-171.
23. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasian: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacokinet 1984; 36: 773-780.